Search results for: Clinical Trial

PARTNER 3 Low-Risk Trial: Co-Principal Investigator Examines 2-Year Outcomes With TAVR

Two-year outcomes data on Transcatheter Aortic Valve Replacement (TAVR) in low-risk patients were recently presented at the American College of Cardiology 2020 Annual Scientific Session. PARTNER 3 demonstrated that TAVR with the Sapien 3 valve was as safe and effective as traditional open surgical replacement for low risk patients with aortic stenosis (AS). The primary outcome of the study—the risk of death, stroke or rehospitalization at two years—was comparable between the two groups.

Read more

Two BSW sites enrolling participants in pivotal device trial for post-amputation residual limb pain

Two Baylor Scott & White sites are participating in a phase III trial examining the safety and efficacy of a device designed to electrically block nerve signals and alleviate pain. Use of this device is being studied in association with providing an effective, mechanism-based yet non-destructive, treatment for managing intractable limb pain in amputees. These locations are the only two sites in the state of Texas selected to participate in this trial.

Read more

Patient-centered research at Baylor Scott & White helps improve care of liver transplant patients

Liver disease is the eighth leading cause of death in the United States and the third or fourth leading cause of death among patients 45 to 64. To improve these outcomes, many hepatologists on the medical staffs of Baylor University Medical Center at Dallas and Baylor Scott & White All Saints Medical Center – Fort Worth are undertaking a number of notable patient-centered research projects. All research projects are administered by Baylor Scott & White Research Institute.

Read more

Dallas site enrolls for global IDE study evaluating use of coronary IVL in the U.S.

Baylor Scott & White Heart & Vascular Hospital Dallas is currently enrolling patients for a prospective, multicenter, single-arm, global investigational device exemption (IDE) study to evaluate the safety and effectiveness of the Shockwave Coronary IVL System in de novo, calcified, stenotic coronary arteries prior to stenting. Disrupt CAD III is being conducted as a staged pivotal study.

Read more